Pharm Exec’s 19th annual report on the trends of the day in drug development examines the surging investment in new treatments and advances for so-called “first-world” conditions.

2024 Pipeline Report: First-World Focus

How pharma companies can reduce the risk of failure with AI-based innovations.

Changing the Paradigm in AI Implementation

A look at the performance of the top 15 companies across seven business-key metrics, including the latest standouts in market capitalization and creating shareholder value.

22nd Annual Industry Audit: The Pharma Value Picture

Check out the latest issue of Pharmaceutical Executive!

Pharmaceutical Executive: November 2023

Articles

FDA approval of bluebird bio’s Lyfgenia and Vertex Pharmaceuticals' and CRISPR Therapeutics’ Casgevy marks significant milestone in the treatment of sickle cell disease.

FDA Approves Two Landmark Cell-Based Gene Therapies for Sickle Cell Disease

Mike Hollan is an assistant managing editor for 

 and can be reached at mhollan@mjhlifesciences.com.

Farbman discusses the struggles that pharma companies are facing when trying to raise funds and how this is impacting IPOs.

Market Trends To Watch in 2024: Q&A With Seth Farbman, Chairman and Co-Founder of VStock Transfer

Pharma companies must embrace the future to advance commercialization.

Embracing the Future: Meeting Doctors and Patients Where They Are Now

PREPVACC study expected to stop further HIV vaccination attempts after previously enrolling 1,500 participants in East and Southern Africa.

Report: Experimental HIV Vaccine Unlikely to be Effective in Preventing Acquisition 

Videos

Camille Lee explains the ins and outs of the patient support system for psoriasis medication. 

Q&A With UCB's Camille Lee on the Bimzelx Navigate Patient Support System

Arthritis, asthma, cancer, cardiovascular diseases, chronic kidney disease, COPD, depression, and diabetes reach the highest recorded levels since the America’s Health Rankings Annual Report began tracking them in 1990.

Prevalence of Eight Chronic Health Conditions Reach Unprecedented Levels in US

Migraine with comorbid obesity have been found to cause high levels of disability and are both more common in female patients.

Teva's Ajovy Shows Similar Efficacy Reducing Migraine Attacks in Patients With Obesity

Trial of Keytruda (pembrolizumab) plus chemotherapy and maintenance Lynparza (olaparib; AstraZeneca, MSD) for the treatment of metastatic squamous non-small cell lung cancer stopped after data did not show a survival benefit.

Merck Halts Phase III Trial of Keytruda Combination for Non-Small Cell Lung Cancer

UCB executive speaks on recent FDA approval of Bimzelx. 

Q&A With UCB's Camille Lee on New Psoriasis Medication Approval 

Miranda Schmalfuhs is the associate group social media editor of 

Pharmaceutical Executive, Pharmaceutical Commerce

 and can be reached at mschmalfuhs@mjhlifesciences.com.

Experts from Hootsuite noted that the primary social media ROI concern for healthcare companies is the time and money it takes to maintain a multi-platform presence. 

Featured Content

2024 Pipeline Report: First-World Focus

Changing the Paradigm in AI Implementation

22nd Annual Industry Audit: The Pharma Value Picture

Pharmaceutical Executive: November 2023